Professional
Added to YB: 2025-10-22
Pitch date: 2025-09-30
NTLA [neutral]
Intellia Therapeutics, Inc.
-47.37%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
Market Cap
$1.0B
Pitch Price
$17.38
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.03
P/E
-2.05
EV/Sales
7.58
Sector
Biotechnology
Category
growth
Show full summary:
Contrarius Global Equity Fund Portfolio Holding: Intellia Therapeutics, Inc.
NTLA (holding update): Leading in-vivo CRISPR with 2 Phase 3 trials for ATTR-CM & hereditary angioedema. One-shot treatments vs competitors' ongoing therapies offer superior patient compliance & economics. High gross margins expected. ATTR market est. $12B by FY28 - even small share material for $2B market cap co.
Read full article (2 min)